Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
Study sponsor: Arrowhead Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-08-30Actual
Enrollment · participants204Actual
Source updated2025-12-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.